Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Management of ET and PV in 2020: Ruxolitinib in Pts with HU-Resistant/Intolerant Pts, Hydroxyurea & Ropeginterferon Alfa-2b in PV
Login to view comments.
Click here to Login
Malignant Hematology